Brief: Tetra Bio-Pharma Receives Positive Opinion For Orphan Drug Designation For Qixleef From The European Medicines Agency
21/10/2021 11:33
Oct 21 (Reuters) - Tetra Bio Pharma Inc TBP.TO :
* TETRA BIO-PHARMA RECEIVES POSITIVE OPINION FOR ORPHAN DRUG
DESIGNATION FOR QIXLEEF™ FROM THE EUROPEAN MEDICINES AGENCY
Source text for Eikon: ID:nCNW5rHYDa
Further company coverage: TBP.TO
((reuters.briefs@thomsonreuters.com;))
Recent news on Tetra Bio Pharma
See all newsBrief: Tetra Bio Receives A Second Clarifax From Health Canada Regarding Reduvo Risk Management Plan
Brief: Tetra Bio-Pharma Announces Results Of Artificial Intelligence Study Of ARDS-003 Combined With Favipiravir
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra And Prepaire Jointly Apply To Barda For Funding